Sihuan Pharmaceutical’s Bireociclib Tablets Gain Approval for Advanced Breast Cancer Treatment

Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has provided an update.

Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd., has received marketing authorization from the National Medical Products Administration for its innovative drug, Bireociclib Tablets, for two indications in HR+/HER2- advanced breast cancer. This approval marks a significant milestone as Bireociclib is the only CDK4/6 inhibitor approved in China for monotherapy in later-line treatment, showcasing the company’s strong R&D capabilities. The drug’s approval is expected to address treatment bottlenecks in breast cancer therapy, offering a promising solution for patients with limited options.

More about Sihuan Pharmaceutical Holdings Group

Sihuan Pharmaceutical Holdings Group Ltd. is a company in the pharmaceutical industry, focusing on the development of innovative drugs. It operates through its subsidiary, Xuanzhu Biopharmaceutical Co., Ltd., which specializes in oncology products.

Average Trading Volume: 30,261,557

Technical Sentiment Signal: Buy

Current Market Cap: HK$6.44B

Learn more about 0460 stock on TipRanks’ Stock Analysis page.